Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 11/20 | 0.37 |
| ▸ | MMP3 | P08254 | 10/20 | 0.37 |
| ▸ | MMP7 | P09237 | 9/20 | 0.37 |
| ▸ | MMP1 | P03956 | 10/20 | 0.36 |
| ▸ | MMP8 | P22894 | 3/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | FCER2 | P06734 | 3/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6983271 | 0.92 | ADAM17 (0.55) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6983616 | 0.92 | ADAM17 (0.55) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6980625 | 0.92 | ADAM17 (0.55) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6983204 | 0.91 | ADAM17 (0.61) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6980715 | 0.90 | ADAM17 (0.53) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6981572 | 0.90 | ADAM17 (0.53) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6983138 | 0.90 | ADAM17 (0.54) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6986150 | 0.90 | ADAM17 (0.52) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6983432 | 0.90 | ADAM17 (0.52) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6986908 | 0.89 | ADAM17 (0.53) | ADAM17MMP2MMP3MMP7MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1089964-B1 | HYDRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2003-10-29 | — | — | EP | disclosed |
| US-6239151-B1 | TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES, OSTEOARTHRITIS, RESPIRATORY DISEASES, TUMORS, CACHEXIA, CARDIOVASCULAR DISEASES, FEVER, HAEMORRHAGE AND SEPSIS, HYDRAZINE DERIVATIVES, | HOFFMANN-LA ROCHE INC. | 2001-05-29 | — | — | US | disclosed |